<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035200</url>
  </required_header>
  <id_info>
    <org_study_id>OAG2002</org_study_id>
    <nct_id>NCT04035200</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of V117957 in Subjects With an Alcohol Use Disorder Who Are Experiencing Insomnia Associated With Alcohol Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imbrium Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imbrium Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in&#xD;
      subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol&#xD;
      cessation, compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Actual">November 6, 2020</completion_date>
  <primary_completion_date type="Actual">November 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of wakefulness after sleep onset (WASO) measured by polysomnography (PSG)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sleep efficiency (SE)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean latency to persistent sleep (LPS)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean total sleep time (TST)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of awakenings (NAW)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>Sleep component as measured by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective sleep quality (sSleep)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective total sleep time (sTST)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective wakefulness after sleep onset (sWASO)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective sleep onset latency (sSOL)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective time in bed (sTIB)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective sleep efficiency (sSE)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective number of awakenings (sNAW)</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective morning sleepiness on awakening</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>Self-reported sleep outcome measured by subject diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders to V117957 1 mg and 2 mg compared to placebo</measure>
    <time_frame>Day 28 (End of Study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of rebound insomnia during the Washout/Follow-up Period</measure>
    <time_frame>Day 22 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next day residual effects as determined by Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next day residual effects as determined by Karolinska Sleepiness Scale (KSS)</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
    <description>The KSS is a 9-point Likert scale (range: 1 = &quot;extremely alert&quot; to 9 = &quot;very sleepy&quot;) that measures sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next day residual effects as determined by Profile of Mood States (POMS) - Brief</measure>
    <time_frame>Baseline, Day 2, Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>V117957 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V117957 tablets taken orally at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V117957 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V117957 tablets taken orally at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match V117957 tablets taken orally at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V117957 tablets</intervention_name>
    <description>V117957 tablets taken orally at bedtime</description>
    <arm_group_label>V117957 1 mg</arm_group_label>
    <arm_group_label>V117957 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets to match V117957</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria include:&#xD;
&#xD;
          -  Male or female, 18-64 years of age with a body weight of 50-100 kg (110-220 lbs) and a&#xD;
             body mass index (BMI) of 18-32 kg/m2.&#xD;
&#xD;
          -  Otherwise healthy as determined by medical evaluation that includes: medical history,&#xD;
             physical examination, neurological exam, laboratory tests, vital signs, and cardiac&#xD;
             monitoring.&#xD;
&#xD;
          -  History of moderate or severe alcohol use disorder (AUD) categorized based on&#xD;
             Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria,&#xD;
             as follows:&#xD;
&#xD;
               -  Moderate as defined by presence of 4-5 of the 11 criteria&#xD;
&#xD;
               -  Severe as defined by the presence of â‰¥ 6 of the 11 criteria.&#xD;
&#xD;
          -  At least 3 weeks and not more than 6 months since last alcoholic beverage intake at&#xD;
             the time of study screening. Any subject who completed an alcohol detoxification&#xD;
             program must be at least 7 days from completion of the program at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Persistent insomnia that emerged or worsened during AUD period, or during or after&#xD;
             alcohol cessation characterized by a study-specific sleep diary.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant and not&#xD;
             breastfeeding. Both females of childbearing potential and nonsurgically sterilized&#xD;
             males with a sexual partner of childbearing potential must be willing to use adequate&#xD;
             and reliable contraception throughout the study.&#xD;
&#xD;
          -  Willing to refrain from a behavioral or other treatment program for insomnia during&#xD;
             participation in the study.&#xD;
&#xD;
        Key Exclusion Criteria include:&#xD;
&#xD;
          -  Current diagnosis of a sleep-related breathing disorder including obstructive sleep&#xD;
             apnea (with or without continuous positive airway pressure (CPAP) treatment), periodic&#xD;
             limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder or&#xD;
             narcolepsy.&#xD;
&#xD;
          -  An apnea-hypopnea index (AHI) score of &gt;10 or a periodic limb movement arousal index&#xD;
             (PLMAI) score of &gt; 15 recorded during the screening period PSG.&#xD;
&#xD;
          -  Documented history of insomnia prior to onset of the alcohol use disorder (AUD), which&#xD;
             did not worsen during the AUD period or during or after alcohol cessation.&#xD;
&#xD;
          -  Comorbid conditions which interfere with normal sleep pattern or the evaluation of&#xD;
             next day residual effects.&#xD;
&#xD;
          -  Any lifetime history of suicidal ideation or behavior.&#xD;
&#xD;
          -  History of or any current conditions that might interfere with drug absorption,&#xD;
             distribution, metabolism, or excretion (including any surgical interventions for&#xD;
             weight loss).&#xD;
&#xD;
          -  Any history of seizures (except related to alcohol withdrawal) or head trauma with&#xD;
             sequelae.&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg) or hepatitis C antibody (anti-HCV).&#xD;
&#xD;
          -  History of diagnosed, active liver disease or elevated liver enzymes/bilirubin.&#xD;
&#xD;
          -  History of kidney stones or renal insufficiency or abnormal kidney function at&#xD;
             screening.&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt; 140 mm Hg systolic / 90 mm Hg diastolic).&#xD;
&#xD;
          -  Use of any medication that affects sleep and/or wake function during the week before&#xD;
             starting the screening period.&#xD;
&#xD;
          -  Subjects currently undergoing treatment of other addictions in addition to alcohol.&#xD;
&#xD;
          -  Excessive caffeine consumption.&#xD;
&#xD;
          -  Positive urine drug screen for prohibited substances, except for cannabis on a&#xD;
             case-by-case basis.&#xD;
&#xD;
          -  History of drug use disorder over the past year, other than&#xD;
             alcohol/nicotine/caffeine/cannabis.&#xD;
&#xD;
          -  Plans to travel across more than 3 time zones in the 2 weeks before screening, or&#xD;
             during study participation.&#xD;
&#xD;
          -  Night or rotating shift worker.&#xD;
&#xD;
          -  Any history and/or current evidence of other medical (eg, cardiac, respiratory,&#xD;
             gastrointestinal, renal, malignancy other than basal cell carcinoma), neurological, or&#xD;
             psychiatric conditions that, in the opinion of the investigator, could affect the&#xD;
             subject's safety or interfere with the study.&#xD;
&#xD;
        Other protocol-specific inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research, Inc.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Centers of the Mid Atlantic</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research - Clinical Research Center of Nevada, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Trials</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <disposition_first_submitted>July 27, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>July 27, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 29, 2021</disposition_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

